Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/69339
Title: Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness
Author: Ruiz de Garibay, Gorka
Herranz, Carmen
Llorente, Alicia
Boni, Jacopo
Serra-Musach, Jordi
Mateo González, Francesca
Aguilar, Helena
Gómez-Baldó, Laia
Petit, Anna
Vidal-Bel, August
Climent, Fina
Hernández-Losa, Javier
Cordero, Álex
González-Suárez, Eva
Sanchez-Mut, Jose Vicente
Esteller, Manel
Llatjós, Roger
Varela, Mar
López, José I.gnacio
García, Nadia
Extremera, Ana I.
Gumà, Anna
Ortega, Raúl
Plà, María Jesús
Fernández, Adela
Pernas, Sònia
Falo, Catalina
Morilla, Idoia
Campos, Miriam
Gil, Miguel
Román, Antonio
Molina-Molina, M.
Ussetti, Piedad
Laporta, Rosalía
Valenzuela, Claudio
Ancochea, Julio
Xaubet, Antoni
Casanova, Álvaro
Pujana Genestar, M. Ángel
Keywords: Càncer de mama
Metàstasi
Marcadors tumorals
Càncer de pulmó
Breast cancer
Metastasis
Tumor markers
Lung cancer
Issue Date: 13-Jul-2015
Publisher: Public Library of Science (PLoS)
Abstract: Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-ß3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0132546
It is part of: PLoS One, 2015, vol. 10, num. 7, p. e0132546
Related resource: http://dx.doi.org/10.1371/journal.pone.0132546
URI: http://hdl.handle.net/2445/69339
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
653578.pdf6.8 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons